NVSEF News and Press, Novartis Ag Basel Akt From 02/02/21

Bolt Biotherapeutics has filed proposed terms for a $150 million IPO. The firm is developing antibody conjugate treatments for various cancers. BOLT has produced early efficacy results for its lead program and has an impressive investor syndicate, so the IPO is worth consideration...

Novartis AG (NVS) Q4 2020 Earnings Conference Call January 26, 2021 08:00 ET Company Participants Samir Shah - Investor Relations Vas Narasimhan - Chief Executive Officer Marie-France Tschudin - President, Novartis Pharmaceuticals Susanne Schaffert - President, Novartis Oncology Harry Kirsch ...

The following slide deck was published by Novartis AG in conjunction with their 2020 Q4 earnings call. For further details see: Novartis AG 2020 Q4 - Results - Earnings Call Presentation

Sana Biotechnology has filed to raise $150 million in a U.S. IPO. The firm is a pre-clinical biopharma using cell engineering technologies for an ambitious pipeline of treatment candidates for cancers, liver, and other diseases. SANA is still very early stage and thus high risk bu...

ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. 2020 was a year of monumental progress in renewable energ...

Veeva is building the Industry Cloud for the global life sciences industry with solutions including a CRM suite, content and data management, and AI-powered data analytics. In Q3, Veeva reported a revenue growth rate of 34% y/y (acceleration) and a healthy gross margin of 72% (q/q imp...

Novartis AG (NVS) 39th Annual J.P. Morgan Virtual Healthcare Conference Call January 11, 2021 11:40 ET Company Participants Vas Narasimham - Chief Executive Officer Conference Call Participants Richard Vosser - J.P. Morgan Presentation Richard Vosser Good afternoon. Welcome to the 39th J.P. M...

Gracell Biotechnologies has filed to raise $100 million in a U.S. IPO, although the final figure may vary. The firm is developing treatments for various cancers using a CAR-T approach. GRCL has produced very promising Phase 1 trial results for its lead candidate. For further...

Pharming Group N.V. has filed to offer an estimated $10.9 million in Registered Holder shares in a U.S. offering. The firm is commercializing a treatment for hereditary angioedema and developing a treatment for pneumonia brought on by the Covid-19 virus. The firm is generating rev...

Tweedy Browne’s 13F portfolio value increased from $2.51B to $2.58B this quarter. The largest five individual stock positions are Berkshire Hathaway, Alphabet, Johnson & Johnson, Cisco Systems, and Baidu, and they account for ~55% of the portfolio. Tweedy Browne increas...